期刊文献+

结缔组织病相关间质性肺疾病继发肺动脉高压的临床分析 被引量:11

Clinical analysis of connective tissue disease with interstitial lung disease complicating pulmonary hypertension
原文传递
导出
摘要 目的分析结缔组织病(connectivetissuedisease,CTD)相关间质性肺疾病(interstitiallungdisease,ILD)继发肺动脉高压(pulmonaryhypertension,PH)的临床表现、肺功能、肺部CT/HRcT、血气及实验室检查等临床资料,探讨CTD-ILD继发PH的特点。方法回顾性分析557例CTD-ILD患者的临床资料,比较CTD-ILD-PH组与CTD-ILD组的临床特点。结果①CTD继发ILD的发病率为27.65%,CTD-ILD发生PH的发病率为13.11%;②CTD-ILD继发PH原发病的发病率由高到低依次为:重叠综合征、混合性结缔组织病、系统性硬化症、系统性红斑狼疮、原发性干燥综合征、多发性肌炎/皮肌炎及类风湿关节炎;③CTD-ILD-PH组患者咳痰、气短、呼吸困难、雷诺现象、皮肤变硬的发生率及静息心率均高于CTI)_ILD组(P值均〈O.05);④CTD-ILD-PH组的肺部CT/HRCT中磨玻璃密度影、网格影、小叶间隔增厚、肺动脉干增粗、心影增大及胸腔积液的发生率高于CTD-ILD组(P值均〈0.05);⑤CTD-ILD-PH组肺功能指标FVC%pred、DLC0%pred及血气指标Pa0:均低于CTD-ILD组(P值均d0.05);⑥CTD-ILD-PH组心脏彩超提示右室内径、右室流出道内径、肺动脉内径及三尖瓣反流速度高于CTD-ILD组(P值均d0.05);⑦ANA抗体及SM抗体阳性者更易继发PH。结论①CTD继发ILD的发病率为27.65%,CTD-ILD发生PH的发病率为13.11%。②重叠综合征、混合性结缔组织病合并ILD时较其他CTD患者更易继发PH;③当CTD-ILD患者出现咳痰、气短、呼吸困难、雷诺现象及心率增快症状时,应完善相关检查,警惕PH的发生;④肺CT/HRCT发现网格影、小叶间隔增厚、肺动脉干增粗及心影增大或心脏超声提示右室大、三尖瓣反流速度增高,应监测肺动脉压;⑤CTD-ILD患者肺功能FVC%pred、Dt。CO%pred及血气PaOz下降明显时,注意发生PH;⑥ANA及SM抗体可作为预测CT胁ILD-PH简单、易行的指标。 Objective To study the clinical features of connective tissue disease (CTD) with interstitial lung disease (ILD) complicating pulmonary hypertension (PH). Methods The clinical data of 557 cases of CTD-ILD were retrospectively analyzed, the clinical characteristics of CTD-ILD-PH group and CTD-ILD group were compared. Results (1) The incidence rate of ILD secondary to CTD was 27.65%,the prevalence rate of CTD-ILD-induced PH was 13.11%. (2)The primary diseases in PH secondary to CTD-ILD according to prevalence rate from high to low were: overlap syndrome, mixed connective tissue disease, systemic sclerosis, systemic lupus erythematosus, primary desiccation syndrome, polymyositis/dermatomyositis, and rheumatoid arthritis. (3) The incidence rates of expectoration, breathless,dyspnea,Raynaud's phenomenon, skin hardens, and resting heart rate of CTD-ILD-PH group were higher than those of CTD-ILD group (all P d0.05). (4)The incidence rates of ground-glass opacity, grid shadow,interlobular septal thickening, thickening of pulmonary artery, heart enlargement and pleural effusion in pulmonary CT/HRCT of CTD-ILD-PH group were higher than those of CTD-ILD group (all P 〈0.05). (5)FVCMpred,DLCO%pred,and PaO2 in CTD-ILD-PH group were lower than those in CTD-ILD group (all P 〈 0.05). (6)The echoeardiography showed that the incidence rates of right ventrieular diameter, right ventricular outflow tract diameter, pulmonary artery diameter and three tricuspid regurgitation velocity in CTD-ILD-PH group were higher than those in CTD-ILD group (all P d0.05). (7) The positive ANA and SM antibodies were prone to secondary PH. Conclusions (1)The incidence rate of ILD secondary to CTD is 27. 65%, the prevalence rate of CTD-ILD-induced PH is 13.11 %. (2)Overlap syndrome or mixed connective tissue disease combined with ILD is more likely to complicating PH than other CTD. (3)When the CTD-ILD patients have expectoration, breathless, dyspnea, Raynaud' s phenomenon,skin hardens and increased heart rate, the relevant inspection should be improved, the occurrence of PH should be alerted. (4) When the lung CT/HRCT shows grid shadow,interlobular septal thickening, pulmonary artery thickening or cardiac ultrasound shows right ventricle enlargement or increased three tricuspid regurgitation velocity,the pulmonary artery pressure should monitored. (5)When FVC%pred,DLCO% pred and PaO2 obviously decrease in patients with CTD-ILD, PH should be paied attention to. (6) ANA and SM antibodied can be used to predict CTD-ILD-PH as simple and feasible indexes.
作者 温海艳 姜莉
出处 《国际呼吸杂志》 2015年第16期1213-1218,共6页 International Journal of Respiration
关键词 结缔组织病 间质性肺疾病 肺动脉高压 心脏彩超 肺CT/HRCT 肺功能 Connective tissue disease Interstitial lung disease Pulmonary hypertension Ultrasoniccardiogram Pulmonary CT/HRCT Lung function
  • 相关文献

参考文献20

  • 1Nadler ST, Edelman JD. Inhaled treprostinil and pulmonary arterial hypertension[J]. Vasc Health Risk Manag, 2010,6 : 1115-1124.
  • 2杨宁,赵成,刘布骏,孙凌云.结缔组织病并发肺动脉高压110例临床分析[J].中华风湿病学杂志,2007,11(9):552-555. 被引量:20
  • 3杜彭,魏蔚,巩路.结缔组织病并发肺动脉高压的临床特点研究[J].天津医科大学学报,2010,16(1):72-74. 被引量:7
  • 4Simonneau G,Robbins IM,Beghetti M,et al. Updated Clinical Classification of Pulmonary Hypertension[J]. J Am Coil Cardiol, 2009,30,54(1 Suppl) : S43-54.
  • 5Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension., the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by theInternational Society of Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J,2009,30(20) :2493-2537.
  • 6Archer SL,Weir EK,Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies[J]. Circulation, 2010,121 (18) : 2045- 2066.
  • 7Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension[J]. N Engl J Med, 2004,351 (14) : 1425-1436.
  • 8陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 9混合性结缔组织病诊断及治疗指南[J].中华风湿病学杂志,2011,15(1):42-45. 被引量:32
  • 10系统性红斑狼疮诊断及治疗指南[J].中华风湿病学杂志,2010,14(5):342-346. 被引量:561

二级参考文献81

共引文献4578

同被引文献71

引证文献11

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部